Fatty Liver and Autoimmune Disease: UK Guide

Fatty liver autoimmune disease is an increasingly recognised clinical overlap, with conditions such as rheumatoid arthritis, lupus, and psoriasis all linked to hepatic steatosis through chronic inflammation, metabolic disruption, and long-term medication use. Fatty liver, now more precisely termed metabolic dysfunction-associated steatotic liver disease (MASLD), can develop silently alongside an autoimmune condition, making awareness and monitoring essential. This article explains which autoimmune conditions carry the greatest liver risk, how fatty liver is diagnosed and managed on the NHS, what lifestyle changes can help, and which warning signs should prompt urgent medical attention.

Can an autoimmune disease cause fatty liver?

Yes, autoimmune diseases can cause fatty liver both directly through immune-mediated inflammation driving insulin resistance and indirectly through medications such as corticosteroids, which promote hepatic fat accumulation.

Yes, autoimmune diseases can contribute to the development of fatty liver, both directly through immune-mediated liver inflammation and indirectly through the medications used to manage them. Fatty liver disease, known medically as hepatic steatosis, occurs when excess fat accumulates in liver cells. When this is not related to alcohol, it is termed metabolic dysfunction-associated steatotic liver disease (MASLD), the term now preferred by UK and international liver specialists over the older label non-alcoholic fatty liver disease (NAFLD).^[1][2] MASLD is distinct from alcohol-related liver disease, which has a separate diagnostic pathway.

Autoimmune conditions can promote fatty liver through several mechanisms. Chronic systemic inflammation, a hallmark of many autoimmune diseases, drives insulin resistance, which in turn encourages fat deposition in the liver.^[3][4] Additionally, long-term corticosteroid use, commonly prescribed for conditions such as rheumatoid arthritis or lupus, is a well-recognised cause of drug-induced hepatic steatosis.^[4][5]

It is important to distinguish autoimmune-related fatty liver from autoimmune hepatitis, which is a separate condition in which the immune system directly attacks liver cells. Both can coexist, and the clinical picture can be complex. A person may have MASLD driven by metabolic factors and also have an autoimmune condition that worsens liver inflammation independently.

If you have an autoimmune condition and are concerned about your liver health, speaking to your GP is the appropriate first step. They can arrange blood tests and imaging to assess liver function and fat content, and refer you to a specialist if needed.

Which autoimmune conditions are most commonly linked to fatty liver?

Rheumatoid arthritis, lupus, psoriasis, type 1 diabetes, and inflammatory bowel disease are most commonly linked to fatty liver, each through distinct mechanisms including chronic inflammation, metabolic syndrome, and immunosuppressant therapy.

Several autoimmune conditions are associated with an increased risk of fatty liver, including rheumatoid arthritis, systemic lupus erythematosus (SLE), psoriasis, type 1 diabetes, and inflammatory bowel disease (IBD). The link varies in strength and mechanism depending on the condition involved.

Rheumatoid arthritis (RA): Chronic inflammation and the use of disease-modifying drugs, particularly methotrexate, are both associated with liver changes. Methotrexate can cause hepatic fibrosis with long-term use, and the risk is increased in people who also have obesity, diabetes, or who drink alcohol.^[6][7] NICE guidance and British Society for Rheumatology (BSR) DMARD monitoring recommendations both advise regular liver function monitoring for patients on this treatment.^[8][11]

Systemic lupus erythematosus (SLE): Lupus can cause lupus hepatitis, and the metabolic effects of corticosteroid therapy increase the risk of MASLD. Patients with SLE also have higher rates of metabolic syndrome, a key driver of fatty liver.

Psoriasis: This inflammatory skin condition is independently associated with MASLD, even after accounting for shared risk factors such as obesity and metabolic syndrome.^[27] Evidence suggests that the degree of skin involvement may correlate with liver fat accumulation, though the precise relationship continues to be studied.

Type 1 diabetes: Although often considered separately from autoimmune disease in clinical discussions, type 1 diabetes is autoimmune in origin. Insulin resistance and glycaemic variability contribute to hepatic fat accumulation even in people using insulin therapy.

Inflammatory bowel disease (IBD): Both Crohn's disease and ulcerative colitis are linked to primary sclerosing cholangitis and other liver complications, as well as MASLD, particularly in those with nutritional challenges or on long-term steroid therapy.

Understanding which condition is driving liver changes is essential for guiding appropriate management.

How is fatty liver diagnosed alongside an autoimmune condition?

Diagnosis uses liver function tests, FIB-4 scoring, and ultrasound as first-line tools, with the ELF test and FibroScan used for further fibrosis stratification in line with NICE guidance (NG49 and DG34).

Fatty liver is typically diagnosed through a combination of blood tests, imaging, and sometimes liver biopsy, and the approach does not differ substantially when an autoimmune condition is also present, though interpretation requires additional care. Many people with fatty liver have no symptoms in the early stages, so diagnosis often follows incidental findings or routine monitoring.

Blood tests are usually the starting point. Liver function tests (LFTs) may show raised alanine aminotransferase (ALT) or aspartate aminotransferase (AST), though these can be normal even when significant fat is present. In people with autoimmune conditions, raised inflammatory markers such as CRP and ESR may complicate interpretation. Specific autoimmune liver antibodies (such as ANA, SMA, and LKM-1) are checked if autoimmune hepatitis is suspected. Other causes of abnormal LFTs, including alcohol use, viral hepatitis, and medication effects, should be considered and excluded as part of the assessment.

Fibrosis risk stratification is an important step in the UK primary care pathway, in line with NICE guidance (NG49). The FIB-4 score, calculated from age, ALT, AST, and platelet count, is used as a first-line tool to estimate the risk of significant liver fibrosis. Where the FIB-4 result is indeterminate or elevated, the Enhanced Liver Fibrosis (ELF) test (a blood-based panel) may be used to further stratify risk, as recommended by NICE (DG34).^[10] Patients with a high ELF score or other indicators of advanced fibrosis should be referred to a hepatologist. Your GP can advise on which tests are appropriate for your situation.

Ultrasound is the most widely used first-line imaging tool for detecting hepatic steatosis on the NHS. It is non-invasive and can identify increased echogenicity consistent with fat accumulation, though its sensitivity is lower when fat content is modest.

FibroScan (transient elastography) is increasingly used in NHS liver clinics to assess liver stiffness, which reflects the degree of fibrosis. This is particularly relevant in autoimmune conditions where fibrosis risk may be elevated by both the disease and its treatment.

Liver biopsy remains the gold standard for staging fibrosis and distinguishing between causes of liver disease, but it is reserved for cases where non-invasive tests are inconclusive or where the clinical picture is complex. Your GP or gastroenterologist will determine which investigations are appropriate based on your individual circumstances.

What treatments are available on the NHS for autoimmune-related fatty liver?

No pharmacological treatment is currently licensed for MASLD on the NHS; management focuses on controlling the autoimmune condition, minimising corticosteroid use, and addressing metabolic risk factors such as obesity and dyslipidaemia.

There is currently no licensed pharmacological treatment specifically for MASLD on the NHS, and management focuses on addressing the underlying causes and associated metabolic risk factors. When fatty liver occurs alongside an autoimmune condition, treatment must be tailored carefully to avoid worsening either condition.

Managing the autoimmune condition: Effective control of the underlying autoimmune disease can reduce systemic inflammation and, in turn, lessen its contribution to liver injury. Rheumatologists, gastroenterologists, and hepatologists may work together to optimise treatment regimens. Where methotrexate is implicated in liver changes, the prescribing team may review the dose or consider alternative agents.

Corticosteroid reduction: Where long-term steroid use is contributing to hepatic steatosis, clinicians will aim to use the lowest effective dose and explore steroid-sparing agents. Abrupt discontinuation of steroids is not safe and should never be attempted without medical supervision.

Metabolic risk factor management: NICE guidance on MASLD (NG49) emphasises the importance of managing obesity, type 2 diabetes, hypertension, and dyslipidaemia. Statins, which are sometimes avoided in liver disease due to concerns about hepatotoxicity, are generally considered safe in MASLD and may be recommended where cardiovascular risk is elevated.^[8][9]

GLP-1 receptor agonists: Medicines such as semaglutide and tirzepatide are being studied for their potential benefit in MASLD and metabolic-associated steatohepatitis (MASH), but they are not currently licensed specifically to treat MASLD.^[16][17] In the UK, semaglutide is available as Ozempic (licensed for type 2 diabetes) and Wegovy (licensed for chronic weight management); tirzepatide is available as Mounjaro (licensed for type 2 diabetes and chronic weight management).^[12][15] NHS access to these medicines depends on individual clinical assessment and local commissioning pathways. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinicians may consider appropriate options following assessment. Mounjaro is one option a prescriber may consider after an online consultation with Bolt Pharmacy, and is only prescribed where clinically appropriate.

Referral to a hepatologist is recommended where fibrosis is suspected, liver function is significantly abnormal, or FIB-4 or ELF results indicate elevated risk.

Side effects and risks to watch for with fatty liver and autoimmune disease

Methotrexate, azathioprine, and NSAIDs all carry hepatotoxic risk, requiring regular liver function monitoring; jaundice, abdominal swelling, or signs of liver decompensation require urgent medical assessment.

People living with both fatty liver and an autoimmune condition face a combination of risks from the diseases themselves and from the medications used to treat them, and awareness of warning signs is important for patient safety. Fatty liver can progress through stages of fibrosis to cirrhosis and, in a minority of cases, to liver failure or hepatocellular carcinoma if left unmanaged.

Medication-related liver risks are particularly relevant in this group. Methotrexate, azathioprine, and non-steroidal anti-inflammatory drugs (NSAIDs) all carry hepatotoxic potential. Regular liver function monitoring is recommended by NICE, the BSR, and individual drug SmPCs for patients on these agents. If LFTs rise significantly, the prescribing clinician should be informed promptly.

Signs that warrant contacting your GP include:

• Persistent fatigue or unexplained weight loss

• Yellowing of the skin or whites of the eyes (jaundice)

• Abdominal swelling or pain in the upper right abdomen

• Dark urine or pale stools

• Easy bruising or bleeding

Signs of liver decompensation, which require urgent assessment, include vomiting blood, black or tarry stools, severe confusion or disorientation, and rapidly worsening jaundice. If you experience any of these, call 999 or go to A&E immediately. For sudden, severe abdominal pain accompanied by vomiting, seek urgent assessment via NHS 111 or attend A&E if symptoms are severe.

Drug interactions are also a concern. Some immunosuppressants affect liver enzyme pathways, altering the metabolism of other medicines. Always inform all prescribers of every medicine you are taking, including over-the-counter products and supplements.

Suspected adverse drug reactions can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This applies to both prescription and over-the-counter medicines and helps the MHRA monitor the safety of medicines in real-world use.

How can lifestyle changes help manage fatty liver with an autoimmune condition?

A Mediterranean-style diet, at least 150 minutes of moderate exercise weekly, and sustained weight loss of 7 to 10 per cent are the most evidence-supported interventions for reducing liver fat in MASLD.

Lifestyle modification is the most evidence-supported intervention for improving fatty liver, and it remains beneficial even when an autoimmune condition is present, though the approach may need to be adapted to account for physical limitations or disease activity. NICE guidance on MASLD (NG49) recommends weight loss, dietary change, and increased physical activity as the cornerstone of management.

Weight management: Clinical evidence, including data cited in NICE NG49 and EASL guidance, indicates that a sustained reduction in body weight of around 7 to 10 per cent can reduce liver fat and improve liver enzyme levels, while even modest weight loss of 3 to 5 per cent may reduce hepatic steatosis. Very rapid or uncontrolled weight loss is not recommended, as it can be associated with worsening liver inflammation and an increased risk of gallstones; any significant dietary change should be discussed with your GP or dietitian.

Diet: A Mediterranean-style diet, rich in vegetables, legumes, wholegrains, fish, and olive oil, and low in ultra-processed foods, refined sugars, and saturated fats, is widely recommended for MASLD. Regarding alcohol, UK Chief Medical Officers (CMO) advise that the lowest risk to health is to drink no more than 14 units per week, spread over three or more days.^[20][21] In the context of existing liver steatosis or fibrosis, many hepatologists advise abstinence from alcohol, as any intake may accelerate liver damage. Your GP or specialist can advise on what is appropriate for your individual situation.

Physical activity: Both aerobic exercise and resistance training have been shown to reduce liver fat independently of weight loss.^[25] UK CMO guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults, alongside muscle-strengthening activities on two or more days per week.^[22][23] For people with autoimmune conditions such as RA or lupus, low-impact activities such as swimming, cycling, or walking may be more appropriate during periods of active disease. A physiotherapist or GP can advise on safe exercise options.

Sleep and stress: Emerging evidence suggests that poor sleep quality and chronic psychological stress contribute to metabolic dysfunction and may worsen both autoimmune disease activity and liver health. Addressing these factors, through sleep hygiene measures or psychological support, forms part of a holistic management approach.

Regular review with your GP or specialist team allows lifestyle progress to be monitored alongside clinical markers.

Scientific References

1. Understanding the evolving nomenclature of steatotic liver disease.
2. Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease.
3. Cardiovascular-Kidney-Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review.
4. Pirfenidone ameliorates dexamethasone-induced steatohepatitis and vascular resistance in rats.
5. Drug-induced Steatohepatitis Caused by Long-term Use of Corticosteroids.
6. Should the theory of methotrexate-induced liver toxicity be abandoned?.
7. Hepatotoxicity From Disease-Modifying Anti-rheumatic Drugs (DMARDs) and Association With Metabolic Syndrome in Rheumatoid Arthritis.
8. Metabolic dysfunction-associated steatotic liver disease (NG49).
9. People with MASLD who are taking statins – NG49 chapter.
10. MRI-based technologies for assessing non-alcoholic fatty liver disease – The diagnostic tests (HTG655); references ELF test recommendation (DG34).
11. Methotrexate – BNF monograph (liver function monitoring guidance).
12. Semaglutide (Wegovy / Ozempic / Rybelsus) – BNF monograph.
13. Tirzepatide (Mounjaro) – BNF monograph.
14. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
15. First GLP-1 tablet for weight loss approved in the UK (semaglutide / Wegovy).
16. Efficacy of GLP-1-based Therapies on MASLD and MASH: A Systematic Review and Meta-analysis.
17. Comparison of pharmacological therapies in MASH for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.
18. Statins and the Cardio-Hepatic Axis: Balancing Cardiovascular Protection with Liver Disease Safety.
19. Safety and efficacy of dyslipidaemia treatment in NAFLD patients: a meta-analysis of randomised controlled trials.
20. Alcohol consumption: advice on low risk drinking.
21. Drink less alcohol – Better Health.
22. Physical activity guidelines: UK Chief Medical Officers' report.
23. UK Chief Medical Officers' physical activity guidelines (full guidance text).
24. Physical activity guidelines for adults aged 19 to 64.
25. Structured Exercise Interventions and Hepatic-Metabolic Outcomes in Adults with MASLD: A Narrative Review of Randomised Controlled Trials.
26. Non-alcoholic fatty liver disease (NAFLD).
27. Identification of Risk Factors Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease in Psoriasis Patients.

Frequently Asked Questions